ROTOP Pharmaka

ROTOP Pharmaka is a well-established, privately-held radiopharmaceutical company based in Dresden, Germany, with roots tracing back to the Central Institute for Nuclear Research Rossendorf. The company operates a dual business model, manufacturing its own portfolio of approved diagnostic and therapeutic radiopharmaceuticals while also offering comprehensive CDMO services to third parties. With a focus on theranostics, ROTOP leverages its expertise in pharmaceutical development, GMP manufacturing, and regulatory affairs to serve the growing nuclear medicine market in Europe and beyond. Its recent approval of RoTecPSMA® in Switzerland highlights its commercial and regulatory execution capabilities.

Integrated radiopharmaceutical development and GMP manufacturing platform specializing in precursor synthesis, cold kit formulation, radiolabeling (for SPECT & PET), process scaling, and theranostic pair development.

ROTOP competes in the radiopharmaceutical manufacturing and CDMO space with larger players like Curium, Novartis (for therapeutics), and other specialized European CDMOs. Its differentiation lies in its integrated service model, deep heritage in radiochemistry, and strong focus on theranostic development from its base in a historically significant nuclear research hub.